Summary:
Cyclic vomiting syndrome (CVS) is a chronic condition in which people have episodes of severe nausea and vomiting that alternate with periods during which they feel normal.
- CVS symptoms are often triggered by stress and frequently occur “out of the blue”
- Many people report that episodes occur early in the morning, with some people reporting a seasonal variation to their symptoms
- CVS can be divided into 4 phases: the prodromal phase, the emetic phase, the recovery phase, and the asymptomatic phase
- People with CVS might also have other medical conditions such as migraine, anxiety, or depression
- Many people with CVS are often misdiagnosed as having the stomach flu, food poisoning, or gastroparesis (slow emptying of the stomach)
Criteria:If you have experienced each of the following, you might have CVS:
- Episodes of vomiting that come on suddenly and last from 1-6 days,
- At least 2 of these episodes in the past 6 months and at least 3 episodes in the past year and,
- Absence of vomiting between episodes (other milder symptoms can be present between episodes)
You might qualify to participate in the CVS Hope study if you:
Are between 18 and 60 years of age
Have received a diagnosis of cyclic vomiting syndrome (CVS)
Are otherwise healthy
You might not qualify if you:
Have a medical or psychiatric condition that would make it unsafe for you to participate
Have a known hypersensitivity or allergy to granisetron or other drugs like granisetron
Qualified Participants May Receive:
Pick up and Drop off
Pick up and Drop off from patient home to clinic is also provided
In addition, to Pick up and Drop Off following reimbursement will be provided for eligible patients.
REIMBURSEMENT FOR PARTICIPATION
You will be paid for the visits you complete according to the following schedule:
Screening (V1): $150
Randomization (V2): $150
Home Treatment Period (up to 12 weeks post-randomization): Pre-0: $50; 0: $50; 2 hrs
post dose: $50; 6 hrs post dose: $50; 12 hrs post dose: $50; 24 hrs post dose: $50
Follow up/Termination (V3): $150